济南前列腺坐浴治疗(济南阳痿早泄能治好不) (今日更新中)

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, July 7 (Xinhua) -- Apple announced Thursday that over 15 billion applications have been downloaded from its App Store by more than 200 million Apple mobile devices users worldwide."Thank you to all of our amazing developers who have filled it with over 425,000 of the coolest apps and to our over 200 million iOS users for surpassing 15 billion downloads," said Phillip Schiller, Apple's senior vice president of worldwide product marketing, in a statement.Launched on July 10, 2008, Apple's digital application distribution platform has been growing at a fast speed. It took nine months to hit one billion downloads and five billion in June 2010. In January, Apple gave a 10,000-U.S. dollar App Store gift card to a user who downloaded the 10 billionth application.In Thursday's statement, the Cupertino, California-based company said it had paid developers 2.5 billion dollars to date.Apple's mobile market place is far ahead of Google's Android Market. At its annual I/O conference in May, Google said there had been 4.5 billion app installs so far. But Google said the growth of its mobile operating system and applications is accelerating with its store hitting another billion downloads every 60 days.Currently, Apple is in a legal battle against Amazon over the use of "Appstore," which the online retailer launched in March to sell mobile applications to Google's Android platform users.On Wednesday, a federal judge denied Apple's request to immediately stop Amazon from using the term "Appstore."Meanwhile, Amazon, Microsoft, HTC, Nokia and Sony Ericsson have filed complaints against Apple in Europe, seeking to get Apple's trademarks for "App Store" and "Appstore" invalidated.

TOKYO, June 19 (Xinhua) -- The Japanese gaming company Sega Corp. said in a statement on Sunday some personal information from more than 1.2 million registered users had been stolen after the website of its subsidiary based in Britain was hacked.The Sega Pass website operated by Sega Europe limited was designed to provide product news. The services were shutdown following the breach detected on Friday. They are still not resumed on the official website of the company late Sunday night and the company said it is investigating the hacking.The company said most of the users of the hacked website are in Europe and North America. A similar cyberattack had troubled the Sony group earlier in April. The hacking affected about 100 million people.

TAIYUAN, May 29 (Xinhua) -- Parents of children with cerebral palsy are going to have a place to turn for help, as the first public foundation to provide aid has been set up in northern Shanxi Province.The Brain Rehabilitation Fund was established on Saturday by the China Population Welfare Foundation (CPWF), which is headquartered in Beijing. The CPWF will cooperate with the Shanxi Cerebral Palsy Hospital, which specializes in curing the brain disease with therapies such as acupuncture and massage.Lan Ye, the deputy secretary general of the CPWF, said the fund aims to relieve the burden of affected families by providing financial assistance and training so parents are able to do the therapy at home. In addition, the fund hopes to reduce the incidence of cerebral palsy by publicizing preventative measures to thwart the disease.More than 6 million suffer from cerebral palsy in China, and among them more than 2 million are children, said Guo Xinzhi, vice president of the Shanxi's Federation of the Disabled."A family needs to spend more than 500,000 yuan (77,000 U.S. dollars) to cure a child with the disease," Guo said. "As 70 percent of the children with cerebral palsy are from poor, mountainous areas, more than 25.7 percent of families cannot afford to pay the medical expenses."On Saturday, 25 parents from Xinjiang Uygur Autonomous Region, Fujian, Henan and Shanxi provinces came to the hospital for free training on helping their children to recover at home.

来源：资阳报